image credit: / Freepik

Forbion-backed biotech raises $138M to develop ALS drug

November 14, 2023

Netherlands-based biotechnology company VectorY Therapeutics has raised 129 million euros, or $138 million, to fund development of brain disease drugs.

The Series A financing, announced Monday, was co-led by venture capital firm Forbion and European investor EQT Life Sciences, alongside new backers that included Merck & Co’s venture arm and the ALS Investment Fund.

According to Forbion, VectorY’s financing is one of the largest funding rounds for a private biotech in Europe this year.

Read More on Biopharma Dive